Intel (INTC) 10-Q 23 Apr 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page shares in Millions	3 Months Ended
	Mar. 27, 2021shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 27, 2021
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-25
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	4,038

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Income Statement [Abstract]
Net revenue	$ 19,673	$ 19,828
Cost of sales	8,819	7,812
Gross margin	10,854	12,016
Research and development	3,623	3,275
Marketing, general and administrative	1,328	1,541
Restructuring and other charges	2,209	162
Operating expenses	7,160	4,978
Operating income	3,694	7,038
Gains (losses) on equity investments, net	368	(111)
Interest and other, net	(156)	(313)
Income before taxes	3,906	6,614
Provision for taxes	545	953
Net income	$ 3,361	$ 5,661
Earnings per share - Basic (in dollars per share)	$ 0.83	$ 1.33
Earnings per share - Diluted (in dollars per share)	$ 0.82	$ 1.31
Weighted average shares of common stock outstanding:
Basic (shares)	4,056	4,266
Diluted (shares)	4,096	4,312

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 3,361	$ 5,661
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(350)	(268)
Actuarial valuation and other pension benefits (expenses), net	13	12
Translation adjustments and other	(15)	(5)
Other comprehensive income (loss)	(352)	(261)
Total comprehensive income	$ 3,009	$ 5,400

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Current assets:
Cash and cash equivalents	$ 5,192	$ 5,865
Short-term investments	2,417	2,292
Trading assets	14,788	15,738
Accounts receivable	7,208	6,782
Inventories	8,487	8,427
Assets Held-for-sale	5,557	5,400
Other current assets	2,124	2,745
Total current assets	45,773	47,249
Property, plant and equipment, net of accumulated depreciation of $79,778 ($77,645 as of December 26, 2020)	57,330	56,584
Equity Investments	5,404	5,152
Other long-term investments	1,409	2,192
Goodwill	26,971	26,971
Identified intangible assets, net	8,408	9,026
Other long-term assets	5,327	5,917
Total assets	150,622	153,091
Current liabilities:
Short-term debt	2,647	2,504
Accounts payable	5,434	5,581
Accrued compensation and benefits	2,757	3,999
Other accrued liabilities	13,313	12,670
Total current liabilities	24,151	24,754
Debt	33,237	33,897
Contract Liabilities	90	1,367
Income taxes payable, non-current	4,605	4,578
Deferred income taxes	3,410	3,843
Other long-term liabilities	5,322	3,614
Contingencies (Note 13)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,038 issued and outstanding (4,062 issued and outstanding as of December 26, 2020)	26,272	25,556
Accumulated other comprehensive income (loss)	(1,103)	(751)
Retained earnings	54,638	56,233
Total stockholders’ equity	79,807	81,038
Total liabilities and stockholders’ equity	$ 150,622	$ 153,091

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Assets
Accumulated depreciation	$ 79,778	$ 77,645
Stockholders’ equity:
Common stock, shares issued	4,038	4,062
Common stock, shares outstanding	4,038	4,062

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 5,865	$ 4,194
Cash flows provided by (used for) operating activities:
Net income	3,361	5,661
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	2,454	2,623
Share-based compensation	425	449
Restructuring and other charges	2,209	162
Amortization of intangibles	448	427
(Gains) losses on equity investments, net	(299)	134
Changes in assets and liabilities:
Accounts receivable	(426)	(796)
Inventories	180	(548)
Accounts payable	303	117
Accrued compensation and benefits	(1,283)	(1,605)
Prepaid supply agreements	(1,566)	(87)
Income taxes	383	753
Other assets and liabilities	(641)	(1,132)
Total adjustments	2,187	497
Net cash provided by operating activities	5,548	6,158
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(3,972)	(3,268)
Additions to held for sale NAND property, plant, and equipment	416	0
Purchases of available-for-sale debt investments	(593)	(513)
Maturities and sales of available-for-sale debt investments	1,232	625
Purchases of trading assets	(5,981)	(3,897)
Maturities and sales of trading assets	6,777	3,660
Other investing	406	(343)
Net cash used for investing activities	(2,547)	(3,736)
Cash flows provided by (used for) financing activities:
Issuance of long-term debt, net of issuance costs	0	10,247
Repayment of debt and debt conversion	0	(1,075)
Proceeds from sales of common stock through employee equity incentive plans	565	503
Repurchase of common stock	(2,301)	(4,229)
Payment of dividends to stockholders	(1,411)	(1,408)
Other financing	(527)	726
Net cash provided by (used for) financing activities	(3,674)	4,764
Net increase (decrease) in cash and cash equivalents	(673)	7,186
Cash and cash equivalents, end of period	5,192	11,380
Supplemental disclosures of noncash investing activities and cash flow information:
Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities	(2,472)	(2,294)
Interest, net of capitalized interest	161	67
Income taxes, net of refunds	$ 172	$ 211

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity Statement - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock and Capital in Excess of Par Value	Common Stock and Capital in Excess of Par ValueCumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)Cumulative Effect, Period of Adoption, Adjusted Balance	Retained Earnings1	Retained Earnings1Cumulative Effect, Period of Adoption, Adjusted Balance	[1]
Total stockholders' equity, beginning at Dec. 28, 2019	$ 77,504		$ 25,261		$ (1,280)		$ 53,523
Common stock, shares outstanding, beginning (in shares) at Dec. 28, 2019			4,290
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	5,661						5,661
Other comprehensive income (loss)	(261)				(261)
Employee equity incentive plans and other	620		$ 620
Employee equity incentive plans (in shares)			17
Share-based compensation	449		$ 449
Temporary equity reduction	155		155
Convertible debt	(750)		(750)
Repurchase of common stock	(4,109)		$ (420)				(3,689)
Repurchase of common stock (in shares)			(71)
Restricted stock unit withholdings	(96)		$ (64)				(32)
Restricted stock unit withholdings (in shares)			(2)
Cash dividends declared	(2,819)						(2,819)
Total stockholders' equity, ending at Mar. 28, 2020	76,354		$ 25,251		(1,541)		52,644
Common stock, shares outstanding, ending (in shares) at Mar. 28, 2020			4,234
Total stockholders' equity, beginning at Dec. 26, 2020	$ 81,038	$ 81,073		$ 25,556		$ (751)		$ 56,268
Common stock, shares outstanding, beginning (in shares) at Dec. 26, 2020	4,062			4,062
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 3,361						3,361
Other comprehensive income (loss)	(352)				(352)
Employee equity incentive plans and other	565		$ 565
Employee equity incentive plans (in shares)			17
Share-based compensation	425		$ 425
Temporary equity reduction	0		0
Convertible debt	0		0
Repurchase of common stock	(2,415)		$ (249)				(2,166)
Repurchase of common stock (in shares)			(40)
Restricted stock unit withholdings	(29)		$ (25)				(4)
Restricted stock unit withholdings (in shares)			(1)
Cash dividends declared	(2,821)						(2,821)
Total stockholders' equity, ending at Mar. 27, 2021	$ 79,807		$ 26,272		$ (1,103)		$ 54,638
Common stock, shares outstanding, ending (in shares) at Mar. 27, 2021	4,038		4,038
[1]	The retained earnings balance as of December 26, 2020 includes an opening balance adjustment made as a result of the adoption of a new accounting standard in 2021.

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Retained Earnings1
Common Stock, Dividends, Per Share, Declared	$ 0.695	$ 0.66

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 27, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the Consolidated Financial Statements in our 2020 Form 10-K where we include additional information about our policies and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	3 Months Ended
	Mar. 27, 2021
Segment Reporting [Abstract]
Operating Segments [Text Block]	Note 2 : Operating Segments We manage our business through the following operating segments: ▪ DCG ▪ IOTG ▪ Mobileye ▪ NSG ▪ PSG ▪ CCG We derive a substantial majority of our revenue from platform products, which are our principal products and considered as one product class. We offer platform products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package. Platform products are used in various form factors across our DCG, IOTG, and CCG operating segments. Our non-platform, or adjacent products, can be combined with platform products to form comprehensive platform solutions to meet customer needs. DCG and CCG are our reportable operating segments. IOTG, Mobileye, NSG, and PSG do not meet the quantitative thresholds to qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. Our Internet of Things portfolio, presented as Internet of Things, is comprised of IOTG and Mobileye operating segments. In 2021, our DCG operating segment includes the results of our Intel ® Optane TM memory business, and our NSG operating segment is composed of our NAND memory business. Refer to "Note 8: Acquisitions and Divestitures" within Notes to Consolidated Condensed Financial Statements for further information on the pending divestiture of our NAND memory business. We have an “all other” category that includes revenue, expenses, and charges such as: ▪ results of operations from non-reportable segments not otherwise presented; ▪ historical results of operations from divested businesses; ▪ results of operations of start-up businesses that support our initiatives, including our foundry business; ▪ amounts included within restructuring and other charges; ▪ a portion of employee benefits, compensation, and other expenses not allocated to the operating segments; and ▪ acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. The CODM, who is our CEO, does not evaluate operating segments using discrete asset information. Operating segments do not record inter-segment revenue. We do not allocate gains and losses from equity investments, interest and other income, or taxes to operating segments. Although the CODM uses operating income to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. Net revenue and operating income (loss) for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Net revenue: Data Center Group Platform $ 4,811 $ 6,427 Adjacent 753 566 5,564 6,993 Internet of Things IOTG 914 883 Mobileye 377 254 1,291 1,137 Non-Volatile Memory Solutions Group 1,107 1,338 Programmable Solutions Group 486 519 Client Computing Group Platform 9,617 8,712 Adjacent 988 1,063 10,605 9,775 All other 620 66 Total net revenue $ 19,673 $ 19,828 Operating income (loss): Data Center Group $ 1,273 $ 3,492 Internet of Things IOTG 212 243 Mobileye 147 88 359 331 Non-Volatile Memory Solutions Group 171 (66) Programmable Solutions Group 88 97 Client Computing Group 4,120 4,225 All other (2,317) (1,041) Total operating income $ 3,694 $ 7,038 Disaggregated net revenue for each period was as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Platform revenue DCG platform $ 4,811 $ 6,427 IOTG platform 840 795 CCG desktop platform 2,644 2,840 CCG notebook platform 6,959 5,857 CCG other platform 1 14 15 15,268 15,934 Adjacent revenue 2 4,405 3,894 Total revenue $ 19,673 $ 19,828 1 Includes our tablet and service provider revenue. 2 Includes all of our non-platform products for DCG, IOTG, and CCG such as modem, Ethernet, and silicon photonics, as well as Mobileye, NSG, and PSG products, as well as revenue included in our "all other" category.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Note 3 : Earnings Per Share We computed basic earnings per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended (In Millions, Except Per Share Amounts) Mar 27, 2021 Mar 28, 2020 Net income available to common stockholders $ 3,361 $ 5,661 Weighted average shares of common stock outstanding—basic 4,056 4,266 Dilutive effect of employee equity incentive plans 40 46 Weighted average shares of common stock outstanding—diluted 4,096 4,312 Earnings per share—basic $ 0.83 $ 1.33 Earnings per share—diluted $ 0.82 $ 1.31 Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan.

Contract Liabilities

Contract Liabilities	3 Months Ended
	Mar. 27, 2021
Revenue from Contract with Customer [Abstract]
Contract Liabilities	Note 4 : Contract Liabilities Contract liabilities consist of prepayments received from customers on long-term prepaid supply agreements toward future product delivery and other revenue deferrals from regular ongoing business activity. Contract liabilities were $396 million as of March 27, 2021 ($1.9 billion as of December 26, 2020). The following table shows the changes in contract liability balances relating to long-term prepaid supply agreements during the first three months of 2021: (In Millions) Prepaid supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (616) Prepaid supply agreements balance as of March 27, 2021 $ 59

Other Financial Statement Detai

Other Financial Statement Details	3 Months Ended
	Mar. 27, 2021
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Inventories (In Millions) Mar 27, 2021 Dec 26, 2020 Raw materials $ 926 $ 908 Work in process 5,758 5,693 Finished goods 1,803 1,826 Total inventories $ 8,487 $ 8,427 Interest and Other, Net Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Interest income $ 37 $ 93 Interest expense (190) (135) Other, net (3) (271) Total interest and other, net $ (156) $ (313) Interest expense in the preceding table is net of $97 million of interest capitalized in the first three months of 2021 ($83 million in the first three months of 2020).

Restructuring and Other Charges

Restructuring and Other Charges	3 Months Ended
	Mar. 27, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges A restructuring program, which is ongoing, was approved in the first quarter of 2020 to further align our workforce with our continuing investments in the business and to execute the planned divestiture of Home Gateway Platform, a division of CCG. These actions are expected to be substantially completed in 2021. Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Employee severance and benefit arrangements $ 6 $ 105 Litigation charges and other 2,203 57 Total restructuring and other charges $ 2,209 $ 162

Investments

Investments	3 Months Ended
	Mar. 27, 2021
Investments and Cash [Abstract]
Investments [Text Block]	Note 7 : Investments Debt Investments Trading Assets Net losses recorded for trading assets still held at the reporting date were $372 million in the first three months of 2021 ($231 million of net losses in the first three months of 2020). Net gains on the related derivatives were $366 million in the first three months of 2021 ($100 million of net gains in the first three months of 2020). Available-for-Sale Debt Investments Available-for-sale investments include corporate debt, government debt, and financial institution instruments. Government debt includes instruments such as non-U.S. government bonds and U.S. agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of March 27, 2021 and December 26, 2020, substantially all time deposits were issued by institutions outside the U.S. T he adjusted cost of our available-for-sale investments was $7.0 billion as of March 27, 2021 and $7.8 billion as of December 26, 2020. The adjusted cost of our available-for-sale investments approximated the fair value for these periods. The fair value of available-for-sale debt investments, by contractual maturity, as of March 27, 2021, was as follows: (In Millions) Fair Value Due in 1 year or less $ 3,596 Due in 1–2 years 341 Due in 2–5 years 1,068 Due after 5 years — Instruments not due at a single maturity date 2,130 Total $ 7,135 Equity Investments (In Millions) Mar 27, 2021 Dec 26, 2020 Marketable equity securities $ 1,523 $ 1,830 Non-marketable equity securities 3,864 3,304 Equity method investments 17 18 Total $ 5,404 $ 5,152 The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Ongoing mark-to-market adjustments on marketable equity securities $ (291) $ (103) Observable price adjustments on non-marketable equity securities 551 79 Impairment charges (38) (143) Sale of equity investments and other¹ 146 56 Total gains (losses) on equity investments, net $ 368 $ (111) 1 Sale of equity investments and other includes realized gains (losses) on sales of non-marketable equity investments, our share of equity method investees' gains (losses) and distributions, and initial fair value adjustments recorded upon a security becoming marketable. Gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Net gains (losses) recognized during the period on equity securities $ 311 $ (140) Less: Net (gains) losses recognized during the period on equity securities sold during the period (85) (7) Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 226 $ (147) Beijing Unisoc Technology Ltd. We account for our interest in Beijing Unisoc Technology Ltd. (Unisoc) as a non-marketable equity security. During the first three months of 2021, we recognized $471 million in observable price adjustments in our investment in Unisoc and as of March 27, 2021 the net book value of the investment is $1.1 billion ($658 million as of December 26, 2020).

Acquisitions and Divestitures

Acquisitions and Divestitures	3 Months Ended
	Mar. 27, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures [Text Block]	Note 8 : Acquisitions and Divestitures Divestitures NAND Memory Business On October 19, 2020, we signed an agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business, including our NAND memory fabrication facility in Dalian, China and certain related equipment and tangible assets (the Fab Assets), our NAND SSD business (the NAND SSD Business), and our NAND memory technology and manufacturing business (the NAND OpCo Business). Our Intel Optane memory business is expressly excluded from the transaction. The transaction will occur over two closings for total consideration of $9.0 billion in cash, of which $7.0 billion will be received upon initial closing, not to occur prior to November 1, 2021, and the remaining $2.0 billion will be received no earlier than March 2025. The consummations of the first closing and the second closing are subject to customary conditions, including the receipt of certain governmental approvals. At the first closing, Intel will sell to SK hynix the Fab Assets and the NAND SSD Business, and SK hynix will assume from Intel certain liabilities related to the Fab Assets and the NAND SSD Business. In connection with the first closing, we and certain affiliates of SK hynix will also enter into a NAND wafer manufacturing and sale agreement pursuant to which we will manufacture and sell to SK hynix NAND memory wafers to be manufactured using the Fab Assets in Dalian, China, until the second closing. We will transfer certain employees, IP, and other assets related to the NAND OpCo Business to separately created, wholly owned subsidiaries of Intel at the first closing. The equity interest of these wholly owned subsidiaries will transfer to SK hynix at the second closing. We have concluded based on the terms of the transaction agreements that the subsidiaries will be variable interest entities for which we are not the primary beneficiary, and accordingly will deconsolidate at the first closing. The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Mar 27, 2021 Dec 26, 2020 Inventories $ 723 $ 962 Property, plant and equipment, net 4,759 4,363 Total assets held for sale $ 5,482 $ 5,325 We ceased recording depreciation on property, plant and equipment as of the date the assets triggered held for sale accounting. Total capital purchases of approximately $1.8 billion expected in 2021 prior to the first closing will be classified as assets held for sale in the Consolidated Condensed Balance Sheets and within additions to held for sale NAND property, plant and equipment on the Consolidated Condensed Statements of Cash Flows.

Borrowings

Borrowings	3 Months Ended
	Mar. 27, 2021
Debt Disclosure [Abstract]
Borrowings	Note 9 : Borrowings In March 2021, we entered into a $5.0 billion variable-rate revolving credit facility which, if drawn, is expected to be used for general corporate purposes. The revolving credit facility matures in March 2026 and had no borrowings outstanding as of March 27, 2021. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. Our senior floating rate notes pay interest quarterly and our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our notes rank equally in right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

Fair Value

Fair Value	3 Months Ended
	Mar. 27, 2021
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Note 10 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Mar 27, 2021 Dec 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 297 $ — $ 297 $ — $ 50 $ — $ 50 Financial institution instruments¹ 2,130 849 — 2,979 2,781 636 — 3,417 Government debt² — 33 — 33 — — — — Reverse repurchase agreements — 1,350 — 1,350 — 1,900 — 1,900 Short-term investments: Corporate debt — 851 — 851 — 428 — 428 Financial institution instruments¹ — 878 — 878 — 1,179 — 1,179 Government debt² — 688 — 688 — 685 — 685 Trading assets: Corporate debt — 4,176 — 4,176 — 3,815 — 3,815 Financial institution instruments¹ 110 2,851 — 2,961 131 2,847 — 2,978 Government debt² — 7,651 — 7,651 — 8,945 — 8,945 Other current assets: Derivative assets 33 410 — 443 48 644 — 692 Loans receivable³ — 214 — 214 — 439 — 439 Marketable equity securities 139 1,384 — 1,523 136 1,694 — 1,830 Other long-term investments: Corporate debt — 1,025 — 1,025 — 1,520 — 1,520 Financial institution instruments¹ — 230 — 230 — 257 — 257 Government debt² — 154 — 154 — 415 — 415 Other long-term assets: Derivative assets — 1,004 14 1,018 — 1,520 30 1,550 Loans receivable³ — — — — — 157 — 157 Total assets measured and recorded at fair value $ 2,412 $ 24,045 $ 14 $ 26,471 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 6 $ 603 $ — $ 609 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 6 $ 612 $ — $ 618 $ — $ 815 $ — $ 815 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 2 investments consist primarily of U.S. agency notes and non-U.S. government debt. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of March 27, 2021 was $144 million (the aggregate carrying value of grants receivable as of December 26, 2020 was $139 million).

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 27, 2021
Equity [Abstract]
Other Comprehensive Income (Loss) [Text Block]	Note 11 : Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first three months of 2021 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 26, 2020 $ 731 $ (1,565) $ 83 $ (751) Other comprehensive income (loss) before reclassifications (334) 5 (19) (348) Amounts reclassified out of accumulated other comprehensive income (loss) (95) 16 — (79) Tax effects 79 (8) 4 75 Other comprehensive income (loss) (350) 13 (15) (352) Balance as of March 27, 2021 $ 381 $ (1,552) $ 68 $ (1,103)

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 27, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments [Text Block]	Note 12 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives at the end of each period were as follows: (In Millions) Mar 27, 2021 Dec 26, 2020 Foreign currency contracts $ 31,349 $ 31,209 Interest rate contracts 14,556 14,461 Other 2,139 2,026 Total $ 48,044 $ 47,696 Fair Value of Derivative Instruments Mar 27, 2021 Dec 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 215 $ 110 $ 551 $ 2 Interest rate contracts 986 — 1,498 — Total derivatives designated as hedging instruments 1,201 110 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 221 404 142 685 Interest rate contracts 6 98 3 128 Equity contracts 33 6 48 — Total derivatives not designated as hedging instruments 260 508 193 813 Total derivatives $ 1,461 $ 618 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and non-current. 2 Derivative liabilities are recorded as other liabilities, current and non-current. 3 The majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 27, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 1,455 $ 1,455 $ (404) $ (1,036) $ 15 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,805 — 2,805 (404) (2,386) 15 Liabilities: Derivative liabilities subject to master 516 — 516 (404) (112) — Total liabilities $ 516 $ — $ 516 $ (404) $ (112) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ — We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges, recognized in other comprehensive income (loss), were $334 million net losses in the first three months of 2021 ($373 million net losses in the first three months of 2020). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first three months of 2021 and 2020, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Consolidated Condensed Statements of Income on Derivatives (In Millions) Mar 27, 2021 Mar 28, 2020 Interest rate contracts $ (512) $ 954 Hedged items 512 (954) Total $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheet in Which the Hedged Item is Included Carrying Amount of the Hedged Item Asset/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Mar 27, 2021 Dec 26, 2020 Mar 27, 2021 Dec 26, 2020 Long-term debt $ (12,983) $ (13,495) $ (986) $ (1,498) The total notional amount of pay-variable and receive-fixed interest rate swaps was $12.0 billion as of March 27, 2021 and as of December 26, 2020. Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended (In Millions) Location of Gains (Losses) Recognized in Income on Derivatives Mar 27, 2021 Mar 28, 2020 Foreign currency contracts Interest and other, net $ 234 $ 154 Interest rate contracts Interest and other, net 23 (77) Other Various 55 (268) Total $ 312 $ (191)

Contingencies

Contingencies	3 Months Ended
	Mar. 27, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies [Text Block]	Note 13 : Contingencies Legal Proceedings We are a party to various legal proceedings, including those noted in this section. In the first quarter of 2021, we accrued a charge of $2.2 billion related to litigation involving VLSI, described below. Excluding this charge, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings or other events could occur. Unfavorable resolutions could include substantial monetary damages. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Except as specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2001, the EC commenced an investigation regarding claims by Advanced Micro Devices, Inc. (AMD) that we used unfair business practices to persuade customers to buy our microprocessors. We received numerous requests for information and documents from the EC and we responded to each of those requests. The EC issued a Statement of Objections in July 2007 and held a hearing on that Statement in March 2008. The EC issued a Supplemental Statement of Objections in July 2008. In May 2009, the EC issued a decision finding that we had violated Article 82 of the EC Treaty and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 (later renumbered as Article 102 by a new treaty) by offering alleged "conditional rebates and payments" that required our customers to purchase all or most of their x86 microprocessors from us. The EC also found that we violated Article 82 by making alleged "payments to prevent sales of specific rival products." The EC imposed a fine in the amount of €1.1 billion ($1.4 billion as of May 2009), which we subsequently paid during the third quarter of 2009, and ordered us to "immediately bring to an end the infringement referred to in" the EC decision. The EC decision contained no specific direction on whether or how we should modify our business practices. Instead, the decision stated that we should "cease and desist" from further conduct that, in the EC's opinion, would violate applicable law. We took steps, which are subject to the EC's ongoing review, to comply with that decision pending appeal. We had discussions with the EC to better understand the decision and to explain changes to our business practices. We appealed the EC decision to the Court of First Instance (which has been renamed the General Court) in July 2009. The hearing of our appeal took place in July 2012. In June 2014, the General Court rejected our appeal in its entirety. In August 2014, we filed an appeal with the European Court of Justice. In November 2014, Intervener Association for Competitive Technologies filed comments in support of Intel’s grounds of appeal. The EC and interveners filed briefs in November 2014, we filed a reply in February 2015, and the EC filed a rejoinder in April 2015. The Court of Justice held oral argument in June 2016. In October 2016, Advocate General Wahl, an advisor to the Court of Justice, issued a non-binding advisory opinion that favored Intel on a number of grounds. The Court of Justice issued its decision in September 2017, setting aside the judgment of the General Court and sending the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. The General Court has appointed a panel of five judges to consider our appeal of the EC’s 2009 decision in light of the Court of Justice’s clarifications of the law. In November 2017, the parties filed initial “Observations” about the Court of Justice’s decision and the appeal and were invited by the General Court to offer supplemental comments to each other’s “Observations,” which the parties submitted in March 2018. Responses to other questions posed by the General Court were filed in May and June 2018. The General Court heard oral argument in March 2020. Pending the final decision in this matter, the fine paid by Intel has been placed by the EC in commercial bank accounts where it accrues interest. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified us and other companies that it had identified security vulnerabilities (now commonly referred to as “Spectre” and “Meltdown”) that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. On January 3, 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. Numerous lawsuits have been filed against Intel and, in certain cases, our current and former executives and directors, in U.S. federal and state courts and in certain courts in other countries relating to the Spectre and Meltdown security vulnerabilities, as well as other variants of these vulnerabilities that have since been identified. As of April 21, 2021, consumer class action lawsuits relating to the above class of security vulnerabilities publicly disclosed since 2018 were pending in the United States, Canada, and Israel. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by Intel's actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the United States, numerous individual class action suits filed in various jurisdictions were consolidated in April 2018 for all pretrial proceedings in the U.S. District Court for the District of Oregon. In March 2020, the court granted Intel's motion to dismiss the complaint in that consolidated action but granted plaintiffs leave to amend. In March 2021, the court granted Intel’s motion to dismiss that amended complaint, but granted plaintiffs leave to further amend in part. In Canada, in one case pending in the Superior Court of Justice of Ontario, an initial status conference has not yet been scheduled. In a second case pending in the Superior Court of Justice of Quebec, a stay of the case is in effect until July 2021. In Israel, two consumer class action lawsuits were filed in the District Court of Haifa. In the first case, the District Court denied the parties' joint motion to stay filed in January 2019, but to date has deferred Intel's deadline to respond to the complaint. Intel filed a motion to stay the second case pending resolution of the consolidated proceeding in the United States, and a hearing on that motion has been scheduled for October 2021. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In addition to these lawsuits, Intel stockholders filed multiple shareholder derivative lawsuits since January 2018 against certain current and former members of our Board of Directors and certain current and former officers, alleging that the defendants breached their duties to Intel in connection with the disclosure of the security vulnerabilities and the failure to take action in relation to alleged insider trading. The complaints sought to recover damages from the defendants on behalf of Intel. Some of the derivative actions were filed in the U.S. District Court for the Northern District of California and were consolidated, and the others were filed in the Superior Court of the State of California in San Mateo County and were consolidated. The federal court granted defendants' motion to dismiss in August 2018 on the ground that plaintiffs failed to plead facts sufficient to show they were excused from making a pre-lawsuit demand on the Board. The federal court granted plaintiffs leave to amend their complaint, but subsequently dismissed the cases in January 2019 at plaintiffs' request. The California Superior Court entered judgment in defendants' favor in August 2020 after granting defendants' motions to dismiss plaintiffs' consolidated complaint and three successive amended complaints, all for failure to plead facts sufficient to show plaintiffs were excused from making pre-lawsuit demand on the Board. Plaintiffs filed a notice of appeal of the California court's judgment in October 2020. In January 2021, another Intel stockholder filed a derivative lawsuit in the Superior Court in San Mateo County against certain current and former officers and members of our Board of Directors. The lawsuit asserts claims similar to those dismissed in August 2020, except that it alleges that the stockholder made a pre-lawsuit demand on our Board of Directors and that the demand was wrongfully refused. Defendants moved to dismiss or stay the action in March 2021, because Intel’s bylaws require such claims to be brought in Delaware. Institute of Microelectronics, Chinese Academy of Sciences v. Intel China, Ltd., et al. In February 2018, the Institute of Microelectronics of the Chinese Academy of Sciences (IMECAS) sued Intel China, Ltd., Dell China, Ltd. (Dell), and Beijing JingDong Century Information Technology, Ltd. (JD) for patent infringement in the Beijing High Court. IMECAS alleges that Intel’s Core series processors infringe Chinese patent CN 102956457 (’457 Patent). The complaint demands an injunction and damages of at least RMB 200,000,000 plus the cost of litigation. A trial date is not yet set. In March 2018, Dell tendered indemnity to Intel, which Intel granted in April 2018. JD also tendered indemnity to Intel, which Intel granted in October 2018. In March 2018, Intel filed an invalidation request on the ‘457 patent with the Chinese Patent Review Board (PRB). The PRB held an oral hearing in September 2018 and in February 2019 upheld the validity of the challenged claims. Intel filed a complaint in April 2019 with the Beijing Intellectual Property Court challenging the February 2019 PRB ruling. In January 2020, Intel filed a second invalidation request on the ‘457 patent with the PRB, for which the PRB heard oral argument in July 2020 and in November 2020 held the challenged apparatus claims invalid. IMECAS filed a complaint in February 2021 with the Beijing Intellectual Property Court challenging the November 2020 PRB ruling. In December 2020, Intel filed a third invalidation request on the ’457 patent with the PRB.  A hearing on Intel’s third PRB invalidation request on the ’457 patent is scheduled for May 2021. In September 2018 and March 2019, Intel filed petitions with the U. S. Patent & Trademark Office (USPTO) requesting institution of inter partes review (IPR) of U.S. Patent No. 9,070,719, the U.S. counterpart to the ‘457 patent. The USPTO denied institution of Intel’s petitions in March and October 2019, respectively. In April 2019, Intel filed a request for rehearing and a petition for a Precedential Opinion Panel (POP) in the USPTO to challenge the denial of its first IPR petition, and in November 2019 Intel filed a request for rehearing on the second IPR petition. In January 2020, the USPTO denied the POP petition on the first IPR petition. In June 2020, the Patent Trial and Appeal Board denied Intel's rehearing requests on both petitions. In October 2019, IMECAS filed second and third lawsuits, in the Beijing IP Court, alleging infringement of Chinese Patent No. CN 102386226 (‘226 Patent) based on the manufacturing and sale of Intel’s Core i3 microprocessors. Defendants in the second case are Lenovo (Beijing) Co., Ltd. (Lenovo) and Beijing Jiayun Huitong Technology Development Co. Ltd. (BJHT). Defendants in the third case are Intel Corp., Intel China Co., Ltd., the Intel China Beijing Branch, Beijing Digital China Co., Ltd. (Digital China), and JD. Both complaints demand injunctions plus litigation costs and reserve the right to claim damages in unspecified amounts. No proceedings have occurred or are yet scheduled in these lawsuits. In December 2019, Lenovo tendered indemnity to Intel, which Intel granted in March 2020. In July 2020, Intel filed two invalidation requests on the '226 patent with the Chinese PRB. The PRB heard oral argument in December 2020, during which IMECAS proposed amendments to two claims. The PRB ruled in April 2021 on both invalidation requests, finding the two amended claims as well as the unamended claims not invalid. Given the procedural posture and the nature of these cases, the unspecified nature and extent of damages claimed by IMECAS, and uncertainty regarding the availability of injunctive relief under applicable law, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, arising from these matters. We dispute IMECAS’s claims and intend to vigorously defend against them. VLSI Technology LLC v. Intel In October 2017, VLSI filed a complaint against Intel in the U.S. District Court for the Northern District of California alleging infringement of eight patents acquired from NXP Semiconductors, N.V. (NXP). The patents, which originated at Freescale Semiconductor, Inc. and NXP B.V., are U.S. Patent Nos. 7,268,588; 7,675,806; 7,706,207; 7,709,303; 8,004,922; 8,020,014; 8,268,672; and 8,566,836. VLSI accuses various FPGA and processor products of infringement. VLSI estimated its damages to be as high as $7.1 billion, and its complaint further sought enhanced damages, future royalties, attorneys’ fees, costs, and interest. In May, June, September, and October 2018, Intel filed IPR petitions challenging the patentability of certain claims in all eight of the patents in-suit. The PTAB instituted review of six patents and denied institution on two patents. As a result of the institution decisions, the parties stipulated to stay the District Court action in March 2019. In December 2019 and February 2020, the PTAB found all claims of the '588 and '303 patents, and some claims of the '922 patent, to be unpatentable. The PTAB found the challenged claims of the '014, '672, and '207 patents to be patentable. Intel moved for a continuation of the stay in March 2020 as it appealed certain rulings by the PTAB. In June 2020, the District Court issued an order continuing the stay through August 2021 and setting trial for December 2022. The Federal Circuit has thus far affirmed the PTAB’s decisions as to the ‘207 and ‘672 patents. In June 2018, VLSI filed a second suit against Intel, in U.S. District Court for the District of Delaware, alleging infringement by various Intel processors of five additional patents acquired from NXP: U.S. Patent Nos. 6,212,663; 7,246,027; 7,247,552; 7,523,331; and 8,081,026. VLSI accused Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys’ fees and costs, and interest. In March 2019, the District Court dismissed VLSI’s claims for willful infringement as to all the patents-in-suit except the ‘027 patent, and also dismissed VLSI’s allegations of indirect infringement as to the ‘633, ‘331, and ‘026 patents. In June 2019, Intel filed requests for inter partes review of the patentability of claims in all five patents-in-suit. In January 2020, the District Court vacated the November 2020 trial date based on agreement of the parties; no trial date is currently set. In January and February 2020, the PTAB instituted review of the '552, '633, '331, and '026 patents and as a result Intel moved for stay of the District Court proceedings. In May 2020, the District Court stayed the case as to the '026 and '552 patents but allowed the case to proceed on the '027 and '331 patents. In January 2021, the PTAB invalidated certain asserted claims of the ‘026 patent, and in February the PTAB invalidated all asserted claims of the ‘552 patent. Intel filed a notice of appeal regarding the PTAB’s decision as to the ‘026 patent in March 2021, and the case remains stayed as to that patent. For the '027 and '331 patents, VLSI is seeking damages of approximately $4.13 billion plus enhanced damages for the '027 patent. VLSI is no longer asserting claims from the '633 patent. In March 2019, VLSI filed a third suit against Intel, also in U.S. District Court for the District of Delaware, alleging infringement of six more patents acquired from NXP: U.S. Patent Nos. 6,366,522; 6,663,187; 7,292,485; 7,606,983; 7,725,759; and 7,793,025. In April 2019, VLSI voluntarily dismissed this Delaware case without prejudice. In April 2019, VLSI filed three new infringement suits against Intel in the U.S. District Court for the Western District of Texas (WDTX) accusing various Intel processors of infringement. The three suits collectively assert the same six patents from the voluntarily dismissed Delaware case plus two additional patents acquired from NXP, U.S. Patent Nos. 7,523,373 and 8,156,357. VLSI accuses Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys’ fees and costs, and interest. In the first Texas case, VLSI asserted the ‘373 and ‘759 patents (in December 2020 the Court granted Intel summary judgment of non-infringement on the ‘357 patent, which had also been asserted in the first Texas case). That case went to trial in February 2021, and the jury awarded a “lump sum” to VLSI of $1.5 billion for literal infringement of the ‘373 patent and $675 million for infringement under the doctrine of equivalents of the ‘759 patent. The jury found that Intel had not willfully infringed either patent. Intel plans to challenge the verdict in post-trial motions and on appeal. The second Texas case went to trial in April 2021, and the jury found that Intel does not infringe the ‘522 and ‘187 patents. The third case is scheduled for trial on June 7, 2021, and VLSI seeks over $1.9 billion for alleged infringement of the ‘983, ‘025 and ‘485 patents, plus enhanced damages for willful infringement. In October and November 2019, and in February 2020, Intel filed IPR petitions on certain asserted claims across six of the patents-in-suit in WDTX. Between May and October 2020, the PTAB denied all of these requests. Intel requested a rehearing and review from the POP as to all petitions. All requests for POP review were denied in October and December 2020, and all requests for rehearing were denied as to all petitions between December 2020 and February 2021. Intel filed notices of appeal regarding the discretionary denials for all petitions in February and March of 2021, and VLSI moved to dismiss those appeals in March 2021. The Federal Circuit has consolidated the 12 appeals into five separate sets. In each of the first three of the consolidated appeals, the Director of the USPTO has intervened in support of VLSI’s motions to dismiss, and the Director has indicated an intent to intervene in the remaining two. The Federal Circuit has not yet ruled on these issues. In May 2019, VLSI filed a case in Shenzhen Intermediate People’s Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201410094015.9 accusing certain Intel Core processors of infringement. VLSI requests an injunction as well as RMB 1.3 million in damages. Defendants filed an invalidation petition in October 2019 with the PRB, but no hearing date has been set. In May 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court has not yet ruled on the motion to stay. The court held the first evidentiary hearing in November 2020. In May 2019, VLSI filed a second case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201080024173.7. VLSI accuses certain Intel core processors and seeks an injunction. Defendants filed with the PRB an invalidation petition in October 2019. No hearing date has been set. In June 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court held its first evidentiary hearing in September 2020. The court held a second evidentiary hearing in December 2020. The court stayed the case in December 2020 pending a determination on invalidity by the PRB. In November 2019, Intel, along with Apple Inc., filed a complaint against Fortress Investment Group LLC, Fortress Credit Co. LLC, Uniloc 2017 LLC, Uniloc USA, Inc., Uniloc Luxembourg S.A.R.L., VLSI, INVT SPE LLC, Inventergy Global, Inc., DSS Technology Management, Inc., IXI IP, LLC, and Seven Networks, LLC. Plaintiffs allege violations of Section 1 of the Sherman Act by certain defendants, Section 7 of the Clayton Act by certain defendants, and California Business and Professions Code section 17200 by all defendants based on defendants' unlawful aggregation of patents. In February 2020, defendants moved to dismiss plaintiffs' complaint. In July 2020, the court granted defendants’ motion to dismiss with leave to amend. The court dismissed antitrust claims related to two DSS patents with prejudice. The plaintiffs filed an amended complaint in August 2020, and defendants moved to dismiss in September 2020. The court heard defendants' motion to dismiss the amended complaint in December 2020 and dismissed plaintiffs’ amended complaint in January 2021, with leave to further amend. In December 2020, the court granted a joint motion by Apple and Seven Networks to dismiss with prejudice Apple’s claims against Seven Networks. Plaintiffs filed a second amended complaint in March 2021. In June 2020, affiliates controlled by Fortress Investment Group, which also controls VLSI, acquired Finjan Holdings, Inc. Intel had signed a “Settlement, Release and Patent License Agreement” with Finjan in 2012, acquiring a license to the patents of Finjan and its affiliates, current or future, through a capture period of November 20, 2022. The agreement also contains covenants wherein Finjan agrees to cause its affiliates to comply with the agreement. As such, Intel maintains that it now has a license to the patents of VLSI, which has become a Finjan affiliate, and that Finjan must cause VLSI to dismiss its suits against Intel. In August 2020, Intel started dispute resolution proceedings under the agreement. As a part of this dispute resolution process, Intel and Finjan held a mediation in December 2020, but failed to resolve their differences. Intel filed suit to enforce its rights under the License Agreement with Finjan in January 2021 in Delaware Chancery Court. In March 2021, defendants filed motions to dismiss the Chancery Court proceedings. In September 2020, Intel filed motions to stay the Texas, Delaware, and Shanghai matters pending resolution of its dispute with Finjan. In November 2020, Intel filed a motion to stay the Shenzhen matter pending resolution of its dispute with Finjan. In November 2020, the Delaware Court denied Intel’s motion to stay. The other stay motions remain pending. Finally, Intel filed a motion to amend its answer in the Texas matters to add a license defense in November 2020, and filed a motion to amend its answer in the Delaware matter to add a license defense in February 2021. The courts have yet to rule on these motions. After consideration of the verdicts in the WDTX cases and the additional pending lawsuits filed by VLSI, Intel accrued a charge of $2.2 billion in the first quarter of 2021. We dispute VLSI’s claims and intend to vigorously defend against them. Litigation Related to 7nm Product Delay Announcement Starting in July 2020, five securities class action lawsuits were filed in the U.S. District Court for the Northern District of California against Intel and certain current and former officers based on Intel’s July 2020 announcement of 7nm product delays. The plaintiffs, who purport to represent classes of acquirers of Intel stock between October 2019 and July 2020, generally allege that the defendants violated securities laws by making false or misleading statements about the timeline for 7nm products in light of subsequently announced delays. In October 2020, the court consolidated the lawsuits and appointed lead plaintiffs, and in January 2021 the lead plaintiffs filed a consolidated complaint. Defendants moved to dismiss the consolidated complaint in March 2021. We dispute the claims described above and intend to defend the lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In addition to the securities lawsuits, several Intel stockholders filed derivative lawsuits against certain members of our Board of Directors and certain current and former officers based on Intel’s July 2020 announcement of 7nm product delays. The complaints, which were filed in the U.S. District Court for the District of Delaware in December 2020, alleged that defendants breached their fiduciary duties to Intel by either making or allowing the company to make alleged misstatements about the timeline for 7nm products during the class period alleged in the securities litigation. Certain of the complaints also alleged claims under Section 14(a) of the Securities Exchange Act of 1934. The court consolidated the cases in January 2021, and ordered plaintiffs to file a consolidated complaint by mid-April 2021. In early April 2021, plaintiffs voluntarily dismissed the action.

Operating Segments (Tables)

Operating Segments (Tables)	3 Months Ended
	Mar. 27, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenue and operating income (loss) for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Net revenue: Data Center Group Platform $ 4,811 $ 6,427 Adjacent 753 566 5,564 6,993 Internet of Things IOTG 914 883 Mobileye 377 254 1,291 1,137 Non-Volatile Memory Solutions Group 1,107 1,338 Programmable Solutions Group 486 519 Client Computing Group Platform 9,617 8,712 Adjacent 988 1,063 10,605 9,775 All other 620 66 Total net revenue $ 19,673 $ 19,828 Operating income (loss): Data Center Group $ 1,273 $ 3,492 Internet of Things IOTG 212 243 Mobileye 147 88 359 331 Non-Volatile Memory Solutions Group 171 (66) Programmable Solutions Group 88 97 Client Computing Group 4,120 4,225 All other (2,317) (1,041) Total operating income $ 3,694 $ 7,038
Revenue from External Customers by Products and Services [Table Text Block]	Disaggregated net revenue for each period was as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Platform revenue DCG platform $ 4,811 $ 6,427 IOTG platform 840 795 CCG desktop platform 2,644 2,840 CCG notebook platform 6,959 5,857 CCG other platform 1 14 15 15,268 15,934 Adjacent revenue 2 4,405 3,894 Total revenue $ 19,673 $ 19,828 1 Includes our tablet and service provider revenue. 2 Includes all of our non-platform products for DCG, IOTG, and CCG such as modem, Ethernet, and silicon photonics, as well as Mobileye, NSG, and PSG products, as well as revenue included in our "all other" category.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended (In Millions, Except Per Share Amounts) Mar 27, 2021 Mar 28, 2020 Net income available to common stockholders $ 3,361 $ 5,661 Weighted average shares of common stock outstanding—basic 4,056 4,266 Dilutive effect of employee equity incentive plans 40 46 Weighted average shares of common stock outstanding—diluted 4,096 4,312 Earnings per share—basic $ 0.83 $ 1.33 Earnings per share—diluted $ 0.82 $ 1.31

Contract Liabilities (Tables)

Contract Liabilities (Tables)	3 Months Ended
	Mar. 27, 2021
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability [Table Text Block]	The following table shows the changes in contract liability balances relating to long-term prepaid supply agreements during the first three months of 2021: (In Millions) Prepaid supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (616) Prepaid supply agreements balance as of March 27, 2021 $ 59

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	3 Months Ended
	Mar. 27, 2021
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Mar 27, 2021 Dec 26, 2020 Raw materials $ 926 $ 908 Work in process 5,758 5,693 Finished goods 1,803 1,826 Total inventories $ 8,487 $ 8,427
Interest and Other, Net [Table Text Block]	Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Interest income $ 37 $ 93 Interest expense (190) (135) Other, net (3) (271) Total interest and other, net $ (156) $ (313)

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	3 Months Ended
	Mar. 27, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Employee severance and benefit arrangements $ 6 $ 105 Litigation charges and other 2,203 57 Total restructuring and other charges $ 2,209 $ 162

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 27, 2021
Investments and Cash [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of available-for-sale debt investments, by contractual maturity, as of March 27, 2021, was as follows: (In Millions) Fair Value Due in 1 year or less $ 3,596 Due in 1–2 years 341 Due in 2–5 years 1,068 Due after 5 years — Instruments not due at a single maturity date 2,130 Total $ 7,135
Investment [Table Text Block]	(In Millions) Mar 27, 2021 Dec 26, 2020 Marketable equity securities $ 1,523 $ 1,830 Non-marketable equity securities 3,864 3,304 Equity method investments 17 18 Total $ 5,404 $ 5,152
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Ongoing mark-to-market adjustments on marketable equity securities $ (291) $ (103) Observable price adjustments on non-marketable equity securities 551 79 Impairment charges (38) (143) Sale of equity investments and other¹ 146 56 Total gains (losses) on equity investments, net $ 368 $ (111) 1 Sale of equity investments and other includes realized gains (losses) on sales of non-marketable equity investments, our share of equity method investees' gains (losses) and distributions, and initial fair value adjustments recorded upon a security becoming marketable. Gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended (In Millions) Mar 27, 2021 Mar 28, 2020 Net gains (losses) recognized during the period on equity securities $ 311 $ (140) Less: Net (gains) losses recognized during the period on equity securities sold during the period (85) (7) Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 226 $ (147)

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	3 Months Ended
	Mar. 27, 2021
Business Combinations [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Mar 27, 2021 Dec 26, 2020 Inventories $ 723 $ 962 Property, plant and equipment, net 4,759 4,363 Total assets held for sale $ 5,482 $ 5,325

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 27, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Mar 27, 2021 Dec 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 297 $ — $ 297 $ — $ 50 $ — $ 50 Financial institution instruments¹ 2,130 849 — 2,979 2,781 636 — 3,417 Government debt² — 33 — 33 — — — — Reverse repurchase agreements — 1,350 — 1,350 — 1,900 — 1,900 Short-term investments: Corporate debt — 851 — 851 — 428 — 428 Financial institution instruments¹ — 878 — 878 — 1,179 — 1,179 Government debt² — 688 — 688 — 685 — 685 Trading assets: Corporate debt — 4,176 — 4,176 — 3,815 — 3,815 Financial institution instruments¹ 110 2,851 — 2,961 131 2,847 — 2,978 Government debt² — 7,651 — 7,651 — 8,945 — 8,945 Other current assets: Derivative assets 33 410 — 443 48 644 — 692 Loans receivable³ — 214 — 214 — 439 — 439 Marketable equity securities 139 1,384 — 1,523 136 1,694 — 1,830 Other long-term investments: Corporate debt — 1,025 — 1,025 — 1,520 — 1,520 Financial institution instruments¹ — 230 — 230 — 257 — 257 Government debt² — 154 — 154 — 415 — 415 Other long-term assets: Derivative assets — 1,004 14 1,018 — 1,520 30 1,550 Loans receivable³ — — — — — 157 — 157 Total assets measured and recorded at fair value $ 2,412 $ 24,045 $ 14 $ 26,471 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 6 $ 603 $ — $ 609 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 6 $ 612 $ — $ 618 $ — $ 815 $ — $ 815 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 2 investments consist primarily of U.S. agency notes and non-U.S. government debt. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance.

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 27, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first three months of 2021 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 26, 2020 $ 731 $ (1,565) $ 83 $ (751) Other comprehensive income (loss) before reclassifications (334) 5 (19) (348) Amounts reclassified out of accumulated other comprehensive income (loss) (95) 16 — (79) Tax effects 79 (8) 4 75 Other comprehensive income (loss) (350) 13 (15) (352) Balance as of March 27, 2021 $ 381 $ (1,552) $ 68 $ (1,103)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 27, 2021
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives at the end of each period were as follows: (In Millions) Mar 27, 2021 Dec 26, 2020 Foreign currency contracts $ 31,349 $ 31,209 Interest rate contracts 14,556 14,461 Other 2,139 2,026 Total $ 48,044 $ 47,696
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments Mar 27, 2021 Dec 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 215 $ 110 $ 551 $ 2 Interest rate contracts 986 — 1,498 — Total derivatives designated as hedging instruments 1,201 110 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 221 404 142 685 Interest rate contracts 6 98 3 128 Equity contracts 33 6 48 — Total derivatives not designated as hedging instruments 260 508 193 813 Total derivatives $ 1,461 $ 618 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and non-current. 2 Derivative liabilities are recorded as other liabilities, current and non-current. 3 The majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheet in Which the Hedged Item is Included Carrying Amount of the Hedged Item Asset/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Mar 27, 2021 Dec 26, 2020 Mar 27, 2021 Dec 26, 2020 Long-term debt $ (12,983) $ (13,495) $ (986) $ (1,498)
Offsetting Assets [Table Text Block]	The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 27, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 1,455 $ 1,455 $ (404) $ (1,036) $ 15 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,805 — 2,805 (404) (2,386) 15 Liabilities: Derivative liabilities subject to master 516 — 516 (404) (112) — Total liabilities $ 516 $ — $ 516 $ (404) $ (112) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Offsetting Liabilities [Table Text Block]	The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 27, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 1,455 $ 1,455 $ (404) $ (1,036) $ 15 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,805 — 2,805 (404) (2,386) 15 Liabilities: Derivative liabilities subject to master 516 — 516 (404) (112) — Total liabilities $ 516 $ — $ 516 $ (404) $ (112) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended (In Millions) Location of Gains (Losses) Recognized in Income on Derivatives Mar 27, 2021 Mar 28, 2020 Foreign currency contracts Interest and other, net $ 234 $ 154 Interest rate contracts Interest and other, net 23 (77) Other Various 55 (268) Total $ 312 $ (191)
Interest and other, net [Member] | Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Consolidated Condensed Statements of Income on Derivatives (In Millions) Mar 27, 2021 Mar 28, 2020 Interest rate contracts $ (512) $ 954 Hedged items 512 (954) Total $ — $ —

Business Segments (Detail)

Business Segments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 19,673	$ 19,828
Operating Income (Loss)	3,694	7,038
Platform
Segment Reporting Information [Line Items]
Net revenue	15,268	15,934
Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	4,405	3,894
DCG platform
Segment Reporting Information [Line Items]
Net revenue	4,811	6,427
Internet of Things [Member]
Segment Reporting Information [Line Items]
Net revenue	1,291	1,137
Operating Income (Loss)	359	331
Client Computing Group [Member]
Segment Reporting Information [Line Items]
Net revenue	10,605	9,775
Operating Income (Loss)	4,120	4,225
Client Computing Group [Member] | Platform
Segment Reporting Information [Line Items]
Net revenue	9,617	8,712
Client Computing Group [Member] | Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	988	1,063
Data Center Group [Member]
Segment Reporting Information [Line Items]
Net revenue	5,564	6,993
Operating Income (Loss)	1,273	3,492
Data Center Group [Member] | Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	753	566
Internet of Things Group [Member]
Segment Reporting Information [Line Items]
Net revenue	914	883
Operating Income (Loss)	212	243
Mobileye [Member]
Segment Reporting Information [Line Items]
Net revenue	377	254
Operating Income (Loss)	147	88
Non-Volatile Memory Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	1,107	1,338
Operating Income (Loss)	171	(66)
Programmable Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	486	519
Operating Income (Loss)	88	97
All other [Member]
Segment Reporting Information [Line Items]
Net revenue	620	66
Operating Income (Loss)	$ (2,317)	$ (1,041)

Product Information (Detail)

Product Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Revenue from External Customer [Line Items]
Net revenue	$ 19,673	$ 19,828
DCG platform
Revenue from External Customer [Line Items]
Net revenue	4,811	6,427
IOTG platform
Revenue from External Customer [Line Items]
Net revenue	840	795
CCG desktop platform
Revenue from External Customer [Line Items]
Net revenue	2,644	2,840
CCG notebook platform
Revenue from External Customer [Line Items]
Net revenue	6,959	5,857
Other platform
Revenue from External Customer [Line Items]
Net revenue	14	15
Platform
Revenue from External Customer [Line Items]
Net revenue	15,268	15,934
Adjacent revenue
Revenue from External Customer [Line Items]
Net revenue	$ 4,405	$ 3,894

Operating Segments Narrative (D

Operating Segments Narrative (Details) - USD ($) $ in Billions	Nov. 01, 2021	Mar. 31, 2025
Forecast
Segment Reporting Information [Line Items]
Proceeds from divestiture	$ 7	$ 2

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Earnings Per Share [Abstract]
Net income	$ 3,361	$ 5,661
Weighted average shares of common stock outstanding—basic	4,056	4,266
Dilutive effect of employee equity incentive plans (shares)	40	46
Weighted average shares of common stock outstanding—diluted	4,096	4,312
Earnings per share - Basic (in dollars per share)	$ 0.83	$ 1.33
Earnings per share - Diluted (in dollars per share)	$ 0.82	$ 1.31

Contract Liabilities (Details)

Contract Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Dec. 26, 2020
Capitalized Contract Cost [Line Items]
Contract with Customer, Liability	$ 396	$ 1,900
Contract with Customer, Liability, Concession Payments	950
Contract liability balance, contract termination		1,600
Prepaid Supply Agreements
Capitalized Contract Cost [Line Items]
Contract with Customer, Liability	59	$ 1,625
Contract with Customer, Liability, Concession Payments	(950)
Contract with Customer, Liability, Revenue Recognized	(616)
Contract with customer, liability, revenue retained in balance	$ 584

Other Financial Statement Det_3

Other Financial Statement Details Inventories (Details) - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Inventory, Net [Abstract]
Raw materials	$ 926	$ 908
Work in process	5,758	5,693
Finished goods	1,803	1,826
Total inventories	$ 8,487	$ 8,427

Other Financial Statement Det_4

Other Financial Statement Details Interest and Other, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Other Nonoperating Income (Expense) [Abstract]
Interest income	$ 37	$ 93
Interest expense	(190)	(135)
Other, net	(3)	(271)
Total interest and other, net	(156)	(313)
Interest Costs Capitalized	$ (97)	$ (83)

Restructuring and Other Charg_3

Restructuring and Other Charges (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 6	$ 105
Litigation charges and other	2,203	57
Restructuring and other charges	2,209	$ 162
Litigation charges	$ 2,200

Investments, Trading Assets (De

Investments, Trading Assets (Detail) - Debt Securities [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Trading, Unrealized Gain (Loss)	$ (372)	$ (231)
Unrealized Gain (Loss) on Derivatives	$ 366	$ 100

Investments, Available-for-Sale

Investments, Available-for-Sale Debt Investments (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	$ 7,000	$ 7,800
Due in 1 year or less	3,596
Due in 1–2 years	341
Due in 2–5 years	1,068
Due after 5 years	0
Instruments not due at a single maturity date	2,130
Total	$ 7,135

Investments, Equity Investments

Investments, Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Dec. 26, 2020
Schedule of Investments [Line Items]
Marketable Securities	$ 1,523		$ 1,830
Cost Method Investments	3,864		3,304
Equity Method Investments	17		18
Equity Investments	5,404		$ 5,152
Mark to market on marketable equity securities1	(291)	$ (103)
Observable price adjustments on non-marketable	551	79
Impairments	(38)	(143)
Other Net Equity Investments	146	56
Gain (Loss) on Investments	368	(111)
Net gains (losses) recognized during the period on equity securities	311	(140)
Less: Net (gains) losses recognized during the period on equity securities sold during the period	(85)	(7)
Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	226	$ (147)
Bejing Unisoc Technology Ltd.
Schedule of Investments [Line Items]
Gain (Loss) on Investments	$ 471

Investments, Equity Method Inve

Investments, Equity Method Investments (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Schedule of Equity Method Investments [Line Items]
Carrying Value, equity method investments	$ 17	$ 18
Marketable Securities	$ 1,523	$ 1,830

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Dec. 26, 2020
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ 368	$ (111)
Bejing Unisoc Technology Ltd.
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	471
Net book value of nonmarketable equity investment	$ 1,100		$ 658

Acquisitions and Divestitures_2

Acquisitions and Divestitures (Details) - USD ($) $ in Billions	Nov. 01, 2021	Oct. 19, 2020	Mar. 31, 2025	Oct. 31, 2021
Business Acquisition [Line Items]
Total consideration		$ 9
Forecast
Business Acquisition [Line Items]
Proceeds from divestiture	$ 7		$ 2
Additions to held for sale NAND property, plant and equipment				$ 1.8

Acquisitions and Divestitures -

Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Business Combinations [Abstract]
Inventories	$ 723	$ 962
Property, plant and equipment, net	4,759	4,363
Total assets held for sale	$ 5,482	$ 5,325

Borrowings Borrowings, Narrativ

Borrowings Borrowings, Narrative (Details)	Mar. 27, 2021USD ($)
Variable Rate Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Variable rate revolving credit facility	$ 5,000,000,000
Commercial Paper
Debt Instrument [Line Items]
Authorization to borrow	$ 10,000,000,000

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Mar. 27, 2021	Dec. 26, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 1,350	$ 1,900
Trading assets, Fair Value Disclosure	14,788	15,738
Derivative assets, Fair Value Disclosure	1,455	2,235
Derivative liabilities, Fair Value Disclosure	516	711
Cost Method Investments	3,864	3,304
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	26,471	30,257
Liabilities, Fair Value Disclosure	618	815
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	144	139
Short-term and Long-term Debt, Fair Value	38,500	40,900
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	4,176	3,815
Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	2,961	2,978
Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	7,651	8,945
Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,523	1,830
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,350	1,900
Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	297	50
Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,979	3,417
Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	33	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	851	428
Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	878	1,179
Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	688	685
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	443	692
Loans receivable, Fair Value Disclosure	214	439
Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,025	1,520
Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	230	257
Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	154	415
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1,018	1,550
Loans receivable, Fair Value Disclosure	0	157
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	609	810
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	9	5
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	2,412	3,096
Liabilities, Fair Value Disclosure	6	0
Level 1 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 1 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	110	131
Level 1 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 1 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	139	136
Level 1 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,130	2,781
Level 1 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	33	48
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	6	0
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	24,045	27,131
Liabilities, Fair Value Disclosure	612	815
Level 2 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	4,176	3,815
Level 2 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	2,851	2,847
Level 2 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	7,651	8,945
Level 2 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,384	1,694
Level 2 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,350	1,900
Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	297	50
Level 2 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	849	636
Level 2 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	33	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	851	428
Level 2 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	878	1,179
Level 2 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	688	685
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	410	644
Loans receivable, Fair Value Disclosure	214	439
Level 2 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,025	1,520
Level 2 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	230	257
Level 2 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	154	415
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1,004	1,520
Loans receivable, Fair Value Disclosure	0	157
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	603	810
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	9	5
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	14	30
Liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	14	30
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss), Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Dec. 26, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	$ 127
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,103)		$ (751)
Other comprehensive income (loss)	(352)	$ (261)
Unrealized holding gains (losses) on available-for-sale investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	381		731
Other comprehensive income (loss) before reclassifications	(334)
Amounts reclassified out of accumulated other comprehensive income (loss)	(95)
Tax effects	79
Other comprehensive income (loss)	(350)
Unrealized holding gains (losses) on derivatives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	(1,552)		(1,565)
Other comprehensive income (loss) before reclassifications	5
Amounts reclassified out of accumulated other comprehensive income (loss)	16
Tax effects	(8)
Other comprehensive income (loss)	13
Actuarial gains (losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	68		83
Other comprehensive income (loss) before reclassifications	(19)
Amounts reclassified out of accumulated other comprehensive income (loss)	0
Tax effects	4
Other comprehensive income (loss)	(15)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	(1,103)		$ (751)
Other comprehensive income (loss) before reclassifications	(348)
Amounts reclassified out of accumulated other comprehensive income (loss)	(79)
Tax effects	75
Other comprehensive income (loss)	$ (352)

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Dec. 26, 2020
Notional Disclosures [Abstract]
Notional amount	$ 48,044		$ 47,696
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,455		2,235
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet			0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,455		2,235
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(404)		(264)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(1,036)		(1,904)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	15		67
Reverse Repurchase Agreements, Gross Amounts Recognized	1,350		1,900
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	1,350		1,900
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(1,350)		(1,900)
Reverse Repurchase Agreements, Net Amount	0		0
Total Assets, Gross Amounts Recognized	2,805		4,135
Total Assets, Gross Amounts Offset in the Balance Sheet	0		0
Total Assets, Net Amounts Presented in the Balance Sheet	2,805		4,135
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(404)		(264)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(2,386)		(3,804)
Total Assets, Net Amount	15		67
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	516		711
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	516		711
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(404)		(264)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(112)		(447)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	0		0
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	512	$ (954)
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0	0
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,461		2,242
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	618		815
Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,201		2,049
Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	110		2
Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	312	(191)
Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	260		193
Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	508		813
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	31,349		31,209
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Gains (Losses) Recognized in Other Comprehensive Income (Loss) on Derivatives (Effective Portion)	334	373
Foreign currency contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	215		551
Foreign currency contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	110		2
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	234	154
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	221		142
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	404		685
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	14,556		14,461
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(512)	954
Interest rate contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	986		1,498
Interest rate contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	0		0
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	23	(77)
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	6		3
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	98		128
Other
Notional Disclosures [Abstract]
Notional amount	2,139		2,026
Other | Not Designated as Hedging Instrument [Member] | Various [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	55	$ (268)
Other | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	33		48
Other | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	6		0
Interest Rate Swap | Long-term Debt | Fair Value Hedging
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000
Derivative, Fair Value, Net	(12,983)		(13,495)
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	$ (986)		$ (1,498)

Contingencies (Detail)

Contingencies (Detail) - 1 months ended May 31, 2009 € in Billions, $ in Billions	EUR (€)	USD ($)
EC Fine [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Paid Value	€ 1.1	$ 1.4